Next, we explored the relationship between ALC, NLR, and clinical outcomes in patients with HER2-positive and HER2-low-expressing breast cancer separately in the T-DXd group (Figs. 4 and 5). This evidence concerns the gene ERBB2 and breast carcinoma.